Who is sponsoring NCT05528913?

NCT05528913 is sponsored by Charite University, Berlin, Germany.

What condition does NCT05528913 study?

NCT05528913 studies Chronic Prurigo.

What drugs are being tested in NCT05528913?

Interventions: Fasenra Prefilled Syringe, Matching Placebo Solution.

What is the status of NCT05528913?

NCT05528913 is currently WITHDRAWN.

Last reviewed 2024-01-04 · How we verify

A Randomized, Double-blind, Placebo-controlled, Phase 2, 12-Week Treatment Study With a 10-Week Follow-up Period to Assess the Efficacy and Safety of Benralizumab (Anti-IL5Rα) in Adult Patients With Chronic Prurigo

NCT05528913 Phase 2 WITHDRAWN

This is a randomized, double-blind, placebo-controlled, Phase 2, 12-Week treatment study with a 10-Week Follow-up period to assess the efficacy and safety of Benralizumab (anti-IL5Rα) in adult patients with chronic prurigo (BICPIC)

Details

Lead sponsor	Charite University, Berlin, Germany
Phase	Phase 2
Status	WITHDRAWN
Start date	2023-10
Completion	2023-10-19

Conditions

Chronic Prurigo

Interventions

Fasenra Prefilled Syringe
Matching Placebo Solution

Primary outcomes

Numerical rating scale of the worst itch (WI-NRS) — Week 0 to week 12
Percent change from baseline in numerical rating scale of the worst itch

Countries

Germany